Pharma Pulse 1/24/25: Clinical Technology Advancements, Encourage Patient Accountability & more

Clinical Technology Advancements in 2024

In a recent video interview with Applied Clinical Trials, Dipanwita Das, CEO & co-founder at Sorcero, discussed advancements and future trends in clinical trials. Key challenges include high costs, long timelines, lack of diversity, and rigid protocols. Das highlighted technological advancements such as AI, real-time monitoring, and historical data analysis, which are all expected to optimize trial design and patient recruitment in 2025 and beyond.

Encourage Patient Accountability for Optimal Medication Safety

Patient-centered care involves educating and empowering individuals to take responsibility for their own care.

Purdue, Sackler Family Reach New $7.4 Billion Opioid Accord

Bankrupt Purdue Pharma LP and members of the billionaire Sackler family agreed to pay $7.4 billion to a group of US states and other parties to settle long-running litigation over OxyContin’s role in the deadly opioid epidemic.

AHF Wins $10+ Million Against Prime Therapeutics in PBM Price-Fixing Arbitration

In a ruling Friday, January 17, Arbitrator Stuart M. Widman found that Prime Therapeutics had violated federal (Sherman Act) and state (Minnesota) antitrust laws in its business dealings with AHF after Prime entered into and performed what was ruled to be a price-fixing collaboration with Express Scripts (ESI), a competing and even larger PBM.

Miranda Schmalfuhs on LinkedIn

On today, #MaternalHealthAwarenessDay (#MHAD) I'd be remiss if I didn't highlight my conversation from September of last year with Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon.

In this episode of the Pharmaceutical Executive podcast, Charlotte and I discuss:
-The broader societal implications of these maternal health issues highlighted in The Commonwealth Fund study
-The most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make
-Specific efforts Organon is undertaking to invest in research, education, and its pipeline to focus on critical areas of need in maternal health
-How her in-practice experience as an OB-GYN are informing Organon's strategic approach to addressing maternal health challenges and much more!

Have a listen below ⬇️

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs